Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/268413 
Autor:innen: 
Erscheinungsjahr: 
2023
Verlag: 
University of California Press, Oakland
Zusammenfassung: 
Capitalizing a Cure takes readers into the struggle over a medical breakthrough to investigate the power of finance over business, biomedicine, and public health. When curative treatments for hepatitis C launched in 2013, sticker shock over their prices intensified the global debate over access to new medicines. Weaving historical research with insights from political economy and science and technology studies, Victor Roy demystifies an oft-missed dynamic in this debate: the reach of financialized capitalism into how medicines are made, priced, and valued. Roy’s account moves between public and private labs, Wall Street and corporate board rooms, and public health meetings and health centers to trace the ways in which curative medicines became financial assets dominated by strategies of speculation and extraction at the expense of access and care. Provocative and sobering, this book illuminates the harmful impact of allowing financial markets to determine who heals and who suffers and points to the necessary work of building more equitable futures.
Schlagwörter: 
capitalization
capital as power
finance
Gilead Sciences
health
pharmaceutical
price
profit
R&D
sabotage
Thorstein Veblen
JEL: 
P16
I1
G
ISBN: 
978-0-520-38872-7
Creative-Commons-Lizenz: 
cc-by-nc-nd Logo
Dokumentart: 
Book
Dokumentversion: 
Published Version
Erscheint in der Sammlung:

Datei(en):
Datei
Größe





Publikationen in EconStor sind urheberrechtlich geschützt.